Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) released its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.56 by ($0.62), Zacks reports. The firm had revenue of $7.91 million during the quarter, compared to analysts' expectations of $16.42 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%.
Fennec Pharmaceuticals Stock Down 5.7 %
Shares of FENC traded down $0.37 during mid-day trading on Thursday, hitting $6.13. The company had a trading volume of 603,592 shares, compared to its average volume of 113,443. The business's 50-day simple moving average is $6.39 and its 200-day simple moving average is $5.63. Fennec Pharmaceuticals has a 1-year low of $3.96 and a 1-year high of $11.49. The stock has a market cap of $168.96 million, a PE ratio of -61.29 and a beta of 0.36.
Analyst Ratings Changes
A number of research analysts have recently commented on FENC shares. Stephens raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th. Wedbush reissued an "outperform" rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Monday. Finally, HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday.
View Our Latest Stock Analysis on FENC
Insider Activity at Fennec Pharmaceuticals
In related news, Director Rosty Raykov sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total value of $67,900.00. Following the transaction, the director now owns 68,725 shares in the company, valued at approximately $466,642.75. This trade represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 31,186 shares of company stock worth $203,389. Company insiders own 10.98% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
